POLE mutations have been identified in 7–12% of endometrial cancers (EMCA), as well as in 1–2% of colorectal cancers, and have been described in rare cases of breast, pancreatic, stomach, lung, ovarian, and brain tumours [6]. This evidence concerns the gene POLE and endometrial cancer.